J&J’s Zytiga Cancer Drug Too Expensive, U.K. Cost Agency Says

A Johnson & Johnson prostate-cancer medicine discovered in England and developed with funds from U.K. charities is too expensive for the country’s National Health Service.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.